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Recurrent respiratory papillomatosis (RRP) is characterised by multiple laryngeal papillomas. Left un-
treated, the lesions enlarge, spread, and endanger the airway. Medical treatments are unsatisfactory, and
repeated surgery remains the mainstay of therapy. RRP is caused by human papillomavirus (HPV) infection.
However, since oral HPV infection is common and RRP is rare, other host and/or viral factors may contribute
to pathogenesis. In an attempt to identify such factors, we have investigated 60 patients. The patients were HLA
class I, II, and tumor necrosis factor TNF typed by sequence-speciﬁc primer PCR, and the results compared
to those for 554 healthy controls by using Fisher’s exact test. Peripheral blood mononuclear cell proliferative
responses of 25 controls and 10 patients to HPV-11 L1 virus-like particles (VLP) were compared. Short-term
VLP-speciﬁc T-cell lines were established, and recognition of L1 was analyzed. Finally, the L1 open reading
frames of HPV isolates from four patients were sequenced. Susceptibility to RRP was associated with HLA
DRB1*0301 (33 of 60 patients versus 136 of 554 controls, P < 0.0001). The three most severely affected patients
were homozygous for this allele. A range of T-cell proliferative responses to HPV-11 VLP were observed in
DRB1*0301-positive healthy donors which were comparable to those in DRB1*0301-negative controls. Indi-
viduals with juvenile-onset RRP also mounted a range of VLP responses, and their magnitude was negatively
correlated with the clinical staging score (P  0.012 by the Spearman rank correlation). DRB1*0301-positive
patients who responded to L1 recognized the same epitope as did matched controls and produced similar
cytokines. Sequencing of clinical isolates excluded the possibility that nonresponsiveness was the result of
mutation(s) in L1.
Recurrent respiratory papillomatosis (RRP) is a life-threat-
ening disease characterised by the growth of multiple benign
tumours in the larynx and other sites within the upper aerodi-
gestive tract. RRP has a bimodal age distribution, with one
peak in early infancy and early childhood and the second in
young adults (15). Although a variety of medical treatments
have been investigated, repeated surgical ablation remains the
mainstay of therapy (15). Despite its rarity (the incidence in
the United States is approximately 1 in 100,000 [5]), the im-
pact of the disease on patients, their families, and health care
systems is immense. It is not unusual for patients to require
more than 100 surgical procedures, and in the United States
the average lifetime costs per juvenile-onset patient exceed
$200,000 (8).
RRP is caused by human papillomavirus (HPV) infection,
usually by HPV-6 and -11 (34), which are more commonly
associated with benign genital warts (21). This led to the hy-
pothesis that juvenile RRP is transmitted from mother to child
during delivery while adult RRP is transmitted sexually (18).
However, in contrast to the low incidence of RRP, genital
HPV infection is common; indeed, it has been estimated that
visible warts are present in 1% of American women of child-
bearing age and that another 15% have evidence of subclinical
infection (21). Furthermore the carriage rate of HPV in the
oropharynx is at least 10% in both children (12, 29) and adults
(23), indicating that other factors must contribute to the patho-
genesis of RRP.
One such factor might be a host immune deﬁcit, although,
since patients do not appear to be more susceptible to other
infectious agents and no consistent immune deﬁcit has previ-
ously been demonstrated (15), any such deﬁcit is likely to be
either subtle or HPV speciﬁc. Susceptibility to a number of
infectious diseases has been associated with polymorphisms in
immune response genes (reviewed by Hill [19]). Of particular
note are reports that susceptibility to cervical cancer, which is
also caused by HPV infection (37), is associated with several
HLA class II alleles (38–40). The role of HLA class II poly-
morphisms in RRP pathogenesis have not been analyzed in
detail, although there is an unconﬁrmed report from a small
study of an association between HLA-DQ3 and disease (see
Discussion) (9).
In this study, we have examined a cohort of 60 patients with
RRP for defects in immune responsiveness. We report a novel
HLA class II disease association, and have gone on to inves-
tigate T-cell proliferative responses to HPV-11 virus-like par-
ticles (VLP) in patients and matched controls.
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Patients and controls. Sixty patients with RRP were recruited from Ear Nose
and Throat clinics in the United Kingdom. Written informed consent was ob-
tained from patients, and ethical approval was obtained from the Multi Centre
Research Ethics Committee for Wales, the Bro Taf Local Research Ethics
Committee, and other appropriate Local Research Ethics Committees. All work
was conducted in accordance with the Helsinki Declaration of 1975 as revised in
1983. Patients were staged using the system of Derkey et al. by an experienced
Ear Nose and Throat surgeon who was blinded to the scientiﬁc data (16). In
brief, disease activity was scored as 0 (none), 1 (surface lesion), 2 (raised lesion),
and 3 (bulky lesion) at 25 sites (13 laryngeal, 6 tracheal, and 6 other).
The controls for the HLA typing were 554 cadaveric organ donors in the
United Kingdom. The representative nature of these controls for the British
population has been established (10). Initially all patients were HLA class II
typed by low-resolution sequence-speciﬁc primer PCR (SSP-PCR) (11) Subse-
quently they were HLA class I and tumor necrosis factor (TNF) typed using
SSP-PCR (11, 17) For cellular studies, venous blood was obtained from 25
healthy, unrelated, adult donors.
HPV typing and HPV L1 sequencing. HPV typing was performed using PCR
with enzyme immunoassay as previously described (20). Sequencing of the L1
gene from HPV-11 was performed on a CEQ 2000 automated sequencer
(Coulter-Beckman, Fullerton, Calif.) using reagents and protocols speciﬁed by
the supplier. All samples were sequenced three times in both directions (primer
details available on request).
Antigens. HPV-11 VLP, composed of the surface coat protein L1, were the gift
Merck Sharp & Dohme (West Point, Pa.) (14). A panel of 95 synthetic 15-mer
peptides spanning the entire sequence of the HPV-11 L1 (accession number
AAC53712) was synthesized by Eurogentec (Seraing, Belguim). Peptides over-
lapped by a minimum of 9 residues. Peptide pools contained ﬁve peptides and
were named by the N-terminal residue of their ﬁrst peptide and the C-terminal
residue of their ﬁnal peptide. Individual peptide sequences and details of peptide
pool composition have been previously described (41).
The sources of the four control antigens were as follows: inﬂuenza A virus/
Beijing/32/92 (H3N2) hemagglutinin was the generous gift of Ruud Brands
(Solvay Duphar B.V., Weesp, The Netherlands); tuberculin puriﬁed protein
derivative (PPD) and absorbed tetanus vaccine were obtained from Evans Med-
ical Ltd., Leatherhead, United Kingdom; and keyhole limpet hemocyanin (KLH)
was obtained from Calbiochem-Behring, La Jolla, Calif.
PBMC responses to HPV L1 and control antigens. Peripheral blood mono-
nuclear cells (PBMC) were examined as previously described (41). In brief,
PBMC were incubated at 0.3  10
6 cells per 1-ml well in 48-well ﬂat-bottom
tissue culture plates (Greiner) for2ha t3 7 °C under 5.8% CO2 in complete
medium (minimal Eagle medium [Sigma, Poole, United Kingdom] with 5%
heat-inactivated pooled AB serum, 100 IU of penicillin-streptomycin (Gibco Life
Technologies, Paisley, United Kingdom), and 2 mM L-glutamine [Gibco]) with
either HPV-11 VLP (1, 5, or 10 g/ml) or positive control antigen (15 go f
tetanus toxoid per ml, 5 go fi n ﬂuenza virus hemagglutinin per ml, 200 U of
PPD per ml, or 10 g of KLH per ml) or complete medium alone (negative
control). The cells were washed, and 0.7  10
6 autologous PBMC were added to
each well. On days 6, 7, and 8 three 80-l aliquots were taken from each well,
pulsed with 0.5 Ci of [
3H]thymidine (Amersham UK Ltd., Little Chalfont,
United Kingdom) per well, and harvested 16 h later. Proliferation was measured
by liquid scintillation spectroscopy. Experiments were conducted in triplicate,
and responses of ﬁve times the geometric mean of controls (T cells, antigen-
presenting cells [APC], and media) were taken to be signiﬁcant. Results are
presented as stimulation indices (SI  cpm of PBMC response to antigen/cpm of
PBMC response to control).
Establishment of CD4
 T-cell lines. HPV-11 L1-speciﬁc T-cell lines were
established as previously described (41), by culturing PBMC at 10
6 cells per 2-ml
well in ﬂat-bottom 24-well tissue culture plates (Greiner) with 10 g of HPV-11
VLP/ml in complete medium at 37°C under 5.8% CO2 for 2 h. The cells were
washed, and 4  10
6 autologous PBMC were added to each well. On day 7, the
emerging line was recovered and restimulated with autologous irradiated (3,000
rads) PBMC prepulsed with HPV-11 VLP (1 g/ml in complete medium).
Restimulated lines were supplemented with 10% (vol/vol) Lymphocult-LT
(Biotest Folex, Frankfurt, Germany) on days 1 and 3. Every 7 days, lines were
recovered and restimulated as above.
Deﬁnition of L1 epitopes. On days 21, 28, and 35 of in vitro culture, the
proliferative responses of emerging lines to HPV-11 VLP and HPV-11 L1 pep-
tide pools were examined. Lines were cultured at 4  10
4 cells/150 ml in compete
medium in 96-well U-bottom tissue culture plates with 10
4 autologous irradiated
(3,000 rads) PBMC prepulsed with medium (control), HPV-11 L1 VLP (1, 5, or
10 g/ml), or L1 peptide pools (19 peptide pools each containing ﬁve peptides).
At 48 h, the cells were pulsed with 0.5 Ci of tritiated thymidine (Amersham
Pharmacia Biotech) per well, harvested, and analyzed as above. Responses of
three times the geometric mean of background (T cells, APC, and medium) were
taken to be signiﬁcant. Responses to individual peptides (5 g/ml) within dom-
inant pools were then examined as detailed above.
Peptide binding competition assay. Binding assays were carried out using the
principle of competition with biotinylated CLIP peptide as previously described
(26).
Analysis of cytokine production by L1-speciﬁc T-cell lines. The production of
gamma interferon (IFN-), interleukin-4 (IL-4), or IL-10 by L1-speciﬁc T-cell
lines was examined using ELISpot kits (Mabtech AB, Nacka, Sweden). Experi-
ments were performed in triplicate as speciﬁed by the manufacturer. After
overnight drying at room temperature, the number of colored spots was deter-
mined under a dissecting microscope.
Statistical analysis. Fisher’s exact test, odds ratio analyses, the Mann-Whitney
test, the Kruskal-Wallis test, and the Spearman rank correlation were carried out
using InStat3 software version 3.0a for Macintosh OS X (Intuitive Software for
Science, San Diego, Calif.). All tests were two sided, and a P value of 0.05 with
a 95% conﬁdence interval was considered signiﬁcant.
RESULTS
Patient demographics and immune screen. Clinical and vi-
rological details for the patients are summarized in Table 1. As
previously reported, the juvenile-onset patients as a group had
undergone more surgical procedures than had the adult-onset
patients (28). The ﬁrst eight patients were screened for a gross
immunological deﬁcit. Studies included enumeration of B cells
(CD19
), immunoglobulin subsets, secretory immunoglobulin
A levels, complement hemolytic activity, T-lymphocyte subsets
(CD3
 CD4
 and CD3
 CD8
), and speciﬁc antibodies
TABLE 1. Clinical and virological details of the patients
Patient type
a No. of
patients
Age (yrs)
% Male
No. of procedures % with 10
procedures in
total
No. of
procedures/patient/yr
Mean Range Mean Range Mean Range
All 50 14.9 0.25–62 52.0 24.6 2–200 55 4.7 0.14–20.0
JORRP 36 4.3 0.25–13 38.0 31.4
b 2–200 73 5.1
c 0.67–20.0
AORRP 24 38.7 17–69 70.0 9.9
b 2–33 26 1.4
c 0.14–3.15
HPV-6 positive 20 12.3 0.25–52 60.0 10.6
d 2–38 46 2.3 0.14–6.80
HPV-11 positive 13 6.5 3.0–35 46.0 34.6
d 2–104 72 5.3 2.0–15.8
a JORRP, juvenile-onset RRP; AORRP, adult-onset RRP.
b The difference in total number of surgical procedures between patients with JORRP and AORRP is signiﬁcant (P  0.01, Mann-Whitney test).
c The difference between patients with JORRP and AORRP in the number of procedures per year is signiﬁcant (P  0.0001 Mann-Whitney test).
d The difference in the total number of procedures between patients with HPV-11 infection and those with HPV-6 infection is signiﬁcant (p  0.03, Mann-Whitney
test), although the apparent difference between these groups in the number of procedures per year is not signiﬁcant (P  0.07 Mann-Whitney test).
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HLA class II typing. Susceptibility to HPV-associated cervi-
cal cancer has been associated with speciﬁc HLA class II alleles
(3, 38–40). To investigate if this was also true of RRP, all
patients were genotyped for HLA class II (HLA-DR, HLA-
DRw, and HLA-DQ) using low-resolution SSP-PCR (Table
2). The most striking ﬁnding was an increase in the number
of HLA-DRB1*03-positive individuals. This association re-
mained statistically signiﬁcant after correction for multiple
comparisons (corrected P  0.0024). DRB1*03 subtyping re-
vealed that all patients were DRB1*0301 positive. Interest-
ingly, the three most severely affected patients were homozy-
gous for DRB1*0301; one has parenchymal lung involvement,
one has severe tracheal and esophageal disease, and one has
severe tracheal disease. Weaker positive associations were also
seen with HLA-DRB1*14 and HLA-DQB1*02 (the latter be-
ing in linkage disequilibrium with HLA-DRB1*03), and a neg-
ative association was seen with HLA-DQB1*03 (previously
reported to be positively associated with RRP [9] [see Discus-
sion]).
HLA class I and TNF typing. HLA-DRB1*0301 is an
important component of the 8.1 extended ancestral HLA hap-
lotype (HLA A-1, B-8, Cw7, DR3, DQ2, TNF-2, termed A1-
B8-DR3). To determine whether the association was with
HLA-DRB1*0301 itself or with other components of this hap-
lotype, HLA class I and TNF typing was undertaken (Table 3).
A signiﬁcant association with the A1-B8-DR3 haplotype was
found in the whole population and in the juvenile-onset pop-
ulation. The TNF haplotype G308G238G488 (frequently
known as TNF-1) was signiﬁcantly decreased, and this was
paralleled by a rise in the TNF haplotype A308G238G488
(TNF-2), a component of the A1-B8-DR3 ancestral haplotype.
HLA analysis as two cohorts of 30 patients. To conﬁrm the
validity of the HLA disease associations described above, we
reexamined our data by treating the ﬁrst 30 patients recruited
as one cohort and the second group of patients as a second
cohort (Table 4). Both the DRB1*0301 and the A1-B8-DR3-
DQ2 disease associations remained signiﬁcant in this analysis.
HLA subgroup analysis by age of onset. We were interested in
determining whether the HLA associations observed in the
whole population remained signiﬁcant when the juvenile- and
adult-onset cohorts were analyzed separately (Table 5). While
the HLA-DRB1*0301 association described above held true in
both subgroups, the HLA-DRB1*14 association was conﬁned
TABLE 2. HLA class II types
HLA allele
d
No. (%) of patients with allele P
Odds ratio 95% conﬁdence
interval RRP (n  60) Control (n  554) Fisher’s exact test Corrected (24)
DRB1*01 9 (0.15) 124 (0.22) NS
a
DRB1*03 33 (0.55) 136 (0.25) 0.0001 0.0024 3.76 2.18–6.47
DRB1*04 19 (0.32) 206 (0.37) NS
DRB1*07 13 (0.22) 147 (0.27) NS
DRB1*08 3 (0.05) 28 (0.05) NS
DRB1*09 1 (0.02) 21 (0.04) NS
DRB1*10 1 (0.02) 10 (0.02) NS
DRB1*11 6 (0.10) 79 (0.14) NS
DRB1*12 0 16 (0.03) NS
DRB1*13 6 (0.10) 102 (0.18) NS
DRB1*14 8 (0.13) 25 (0.05) 0.01 NS 3.26 1.40–7.58
DRB1*15 10 (0.17) 8 (0.20) NS
DRB1*16 1 (0.02) 6 (0.01) NS
DRB3*0x 41 (0.68) 319 (0.58) NS
DRB4*0101–5 28 (0.47) 301 (0.54) NS
DRB5*01/02/03 11 (0.18) 164 (0.30) NS
DQB1*02 36 (0.60) 232 (0.42) 0.009 NS 2.08 1.21–3.59
DQB1*03 29 (0.48) 364 (0.66) 0.01 NS 0.46 0.27–0.78
DQB1*0301/4 19 (0.32) 71 (0.38)
b NS
DQB1*0302/7/8 4 (0.07) 36 (0.19)
b NS
DQB1*0303 5 (0.08) 19 (0.10)
b NS
DQB1*04 3 (0.05) 21 (0.04) NS
DQB1*05 20 (0.33) 88 (0.16)
c NS
DQB1*06 15 (0.25) 108 (0.19)
c NS
a NS, not signiﬁcant.
b DQ3 subtypes had 169 controls.
c DQ5 and DQ6 subtypes had 169 controls.
d HLA DR and DQ alleles do not add up to twice number of donors because of homozygosity.
TABLE 3. HLA class I and TNF types
HLA allele
No. (%) of patients
with allele P (Fisher’s
exact test)
Odds
ratio
95%
conﬁdence
interval RRP
(n  60)
Control
(n  554)
A*01 27 (0.45) 172 (0.31) 0.04 1.82 1.06–3.12
B*08 21 (0.35) 133 (0.24) NS
b (0.08) 1.70 0.97–3.00
B*27 8 (0.13) 40 (0.07) NS (0.12) 1.98 0.88–4.50
C*w7 35 (0.58) 248 (0.47) NS (0.06) 1.73 1.01–2.96
TNF-GGG* 45 (0.76) 103
a (0.93) 0.004 0.25 0.10–0.64
TNF-AGG* 32 (0.54) 35
a (0.32) 0.005 2.57 1.34–4.93
A1B8DR3DQ2 17 (0.28) 61 (0.11) 0.0007 3.20 1.72–5.95
a TNF comparisons used 111 controls and 59 patients since insufﬁcient DNA
was obtained from one patient with juvenile-onset RRP.
b NS, not signiﬁcant.
VOL. 77, 2003 HLA CLASS II AND RRP 1929to the juvenile patients and an additional association with
HLA-B*27 was observed in the adult-onset patients.
HLA subgroup analysis by HPV type. HLA associations in
cervical cancer appear to be HPV type speciﬁc (3). We were
therefore interested in discovering whether HLA associations
in RRP were type speciﬁc. Papilloma biopsy samples were
available from 33 patients; HPV-6 was detected in 20 patients,
and HPV-11 was detected in 13 patients. No examples of
multiple HPV infection was seen. Patients with HPV-11 infec-
tion had more aggressive disease than did those infected with
HPV-6 (Table 1). Of the 13 HPV-11-positive patients, 11 were
HLA DRB1*0301 positive, while of the 20 HPV-6-positive
patients, 9 were DRB1*0301 positive, although this apparent
difference did not attain statistical signiﬁcance.
TABLE 4. Data analyzed as two independent cohorts
HLA allele
No. (%) of patients with allele
P (Fisher’s exact test) Odds ratio 95% conﬁdence
interval RRP Control
First 30 patients (control n  554)
A*01 14 (0.47) 172 (0.31) NS
b
B*08 10 (0.33) 133 (0.24) NS
DRB1*03 15 (0.50) 136 (0.25) 0.004 3.07 1.46–6.45
DRB1*14 3 (0.10) 25 (0.05) NS
DQB1*02 17 (0.57) 232 (0.42) NS
TNF-GGG
a 21 (0.70) 103 (0.93) 0.002 0.18 0.06–0.52
TNF-AGG
a 15 (0.50) 35 (0.32) NS
A1B8DR3DQ2 8 (0.27) 61 (0.11) 0.02 2.94 1.25–6.89
Second 30 patients (control n  554)
A*01 13 (0.43) 172 (0.31) NS
B*08 11 (0.37) 133 (0.24) NS
DRB1*03 18 (0.60) 136 (0.25) 0.0001 4.61 2.17–9.82
DRB1*14 5 (0.17) 25 (0.05) 0.01 4.23 1.50–11.98
DQB1*02 19 (0.63) 232 (0.42) 0.02 2.40 1.12–5.14
TNF-GGG
a 24 (0.80) 103 (0.93) NS
TNF-AGG
a 17 (0.57) 35 (0.32) 0.01 3.08 1.33–7.13
A1B8DR3DQ2 9 (0.30) 61 (0.11) 0.006 3.46 1.52–7.91
a TNF comparisons used 111 controls in both cohorts, and 29 patients in the second cohort.
b NS, not signiﬁcant.
TABLE 5. Comparison of juvenile- and adult-onset subgroups of patients with RRP
HLA allele
b
No. (%) of patients with allele
P (Fisher’s exact test) Odds ratio 95% conﬁdence
interval RRP Control
JORRP (n  36, control n  554)
A*01 18 (0.50) 172 (0.31) 0.03 2.22 1.13–4.37
B*08 13 (0.36) 133 (0.24) NS
c (0.11) 1.79 0.88–3.63
B*27 2 (0.06) 40 (0.07) NS (1.0) 0.76 0.18–3.26
C*w7 22 (0.61) 248 (0.47) NS (0.06) 1.94 0.97–3.87
DRB1*03 21 (0.56) 136 (0.25) 0.0001 4.30 2.16–8.58
DR1*14 6 (0.16) 25 (0.05) 0.008 4.23 1.61–11.10
DQB1*02 23 (0.62) 232 (0.42) 0.01 2.46 1.22–4.95
DQB1*03 18 (0.5) 364 (0.66) NS (0.07) 0.52 0.27–1.03
TNF-GGG
a 27 (0.77) 103
a (0.93) 0.03 0.26 0.09–0.76
TNF-AGG
a 20 (0.57) 35
a (0.32) 0.009 2.9 1.33–6.32
A1B8DR3DQ2 12 (0.33) 61 (0.11) 0.0006 4.04 1.92–8.49
AORRP (n  24, control n  554)
A*01 9 (0.38) 172 (0.31) NS (0.51) 1.83 0.57–3.11
B*08 8 (0.33) 133 (0.24) NS (0.33) 1.58 0.66–3.78
B*27 6 (0.25) 40 (0.07) 0.008 4.28 1.61–11.40
C*w7 13 (0.54) 248 (0.47) NS (0.41) 1.46 0.64–3.31
DRB1*03 12 (0.44) 136 (0.25) 0.008 3.07 1.35–7.00
DRB1*14 2 (0.06) 25 (0.05) NS (0.31) 1.92 0.43–8.64
DQB1*02 13 (0.50) 232 (0.42) NS (0.29) 1.64 0.72–3.73
DQB1*03 10 (0.44) 364 (0.66) 0.03 0.37 0.16–0.86
TNF-GGG
a 18 (0.75) 103
a (0.93) 0.02 0.23 0.07–0.75
TNF-AGG
a 12 (0.50) 35
a (0.32) NS (0.10) 2.17 0.89–5.31
A1B8DR3DQ2 5 (0.21) 61 (0.11) NS (0.18) 2.13 0.77–5.90
a TNF comparisons used 111 controls and 35 juvenile-onset patients.
b JORRP, juvenile-onset RRP; AORRP, adult-onset RRP.
c NS, not signiﬁcant.
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genetic analysis detailed above suggested an HLA class II
disease association, particularly with HLA-DRB1*0301, and
raised the possibility that aberrant CD4
 T-cell responses to
HPV-6 and HPV-11 might underlie the pathogenesis of RRP.
Since HPV-11 does not grow in tissue culture, it is difﬁcult to
examine T-cell responses to the intact virus directly. We there-
fore elected to investigate T-cell proliferative responses to
HPV-11 VLP (see Discussion) and four control antigens (tet-
anus toxoid, inﬂuenza virus hemagglutinin, PPD, and KLH).
When 25 normal controls were examined, all responded to at
least two control antigens (SI 5 [data not shown]) and 20,
including all 6 who were DRB1*0301 positive, demonstrated
signiﬁcant proliferative responses to the HPV-11 VLP (Fig. 1).
No signiﬁcant differences in the magnitude of the response
were seen between DRB1*0301-negative and DRB1*0301-
positive donors (For DRB1*0301-negative controls, mean
SI  19.0; for DRB1*0301-positive controls, mean S.I.  24.0
[P  0.14 by the Mann-Whitney test]).
Cellular responses to HPV-11 VLP in patients with RRP.
The proliferative responses of 10 patients with RRP (7 juvenile
onset and 3 adult onset [clinical summaries are given in Table
6]) to the same panel of antigens was then examined. Nine
recognized at least three control antigens; the exception was
patient 1, who responded only to tetanus toxoid (Fig. 2). As
regards recognition of the HPV-11 VLP, a very similar range
FIG. 1. Proliferative responses to HPV-11 L1 VLP. Proliferative responses of PBMC to HPV-11 VLP from DRB1*0301-positive and -negative
controls and DRB1*0301-positive and -negative patients with RRP, as assessed by [
3H]thymidine incorporation. PBMC were incubated with either
HPV-11 L1 VLP (1, 5, or 10 g/ml) or complete medium (control). On days 6, 7, and 8, three 80-l aliquots were taken from each emerging line,
pulsed with 0.5 Ci of tritiated thymidine per well, and harvested 16 h later. Proliferation was measured by liquid scintillation spectroscopy.
Experiments were conducted in triplicate, and a response ﬁve times the geometric mean of controls (T cells, APC, and medium) was taken to be
signiﬁcant. Results are presented as SI and represent the strongest response seen during the course of the experiment. No signiﬁcant differences
were seen among the four groups either as a whole (P  0.43 by the Kruskal-Wallis test [nonparametric analysis of variance]) or when pairs of
groups were compared using the Mann-Whitney test: DRB1*0301-positive controls versus DRB1*0301-negative controls, P  0.14; DRB1*0301-
positive patients versus DRB1*0301-positive controls, P  0.31; DRB1*0301-negative patients versus DRB1*0301-negative controls, P  0.30;
DRB1*0301-positive versus DRB1*0361-negative patients, P  0.91.
TABLE 6. Clinical summaries for patients—cellular experiments
Patient
no.
Juvenile or
adult onset Site of disease Notes
1 Juvenile Larynx, trachea, and lung Recently developed squamous cell carcinoma of lung
2 Juvenile Larynx In remission when seen 2 mo after venesection
3 Juvenile Single lesion at carina Previously laryngeal, tracheal, and esphogeal disease
4 Juvenile Larynx and trachea Has tracheostomy, and currently no attempt is being made to clear larynx
5 Juvenile None In remission for 15 yr; previously 200 surgical procedures
7 Juvenile Larynx and trachea
8 Juvenile Larynx and trachea Improving, as evidenced by decreased staging score and increasing
intervals between procedures
14 Adult Larynx and subglottis
22 Adult Larynx Relapsed to staging score of 14 within 3 mo of venesection
23 Adult Larynx
VOL. 77, 2003 HLA CLASS II AND RRP 19311932of responses was seen to that previously observed in normal
controls (Fig. 1 and 2): In particular, no signiﬁcant differences
were seen between DRB1*0301-positive patients and positive
controls, between DRB1*0301-negative patients and negative
controls, between DRB1*0301-positive and negative patients.
Given that the patients in this study had a wide range of
clinical phenotypes, ranging from remission through parency-
hmal lung disease (Table 6), we were curious to discover if
there was any relationship between the magnitude of their
proliferative T-cell responses to HPV-11 VLP and their clinical
status when formally staged by the system of Derkay et al. (16).
Because of the differences in clinical phenotype between juve-
nile- and adult-onset RRP (both noted above and previously
described [15]), the two groups of patients were analyzed sep-
arately (Fig. 3). Interestingly, a signiﬁcant negative correlation
was seen between the clinical staging of patients with juvenile-
onset RRP and the SI of their proliferative response to the
HPV-11 VLP (P  0.012, Spearman rank correlation). No such
association was seen between clinical status and responses to
any of the four control antigens (Fig. 4).
Proliferative studies were carried out on three patients with
adult onset disease. While the small size of this group makes it
difﬁcult to draw ﬁrm conclusions, as a group they mounted
weak responses to the VLP (Fig. 3).
Fine speciﬁcity of cellular responses to HPV-11 VLP. To
establish whether the subset of DRB1*0301 patients who re-
sponded to the HPV-11 VLP recognized the same L1 epitopes
as did the DRB1*0301-positive controls, CD4
 T-cell re-
sponses to HPV-11 VLP were mapped by using short-term
CD4
 T-cell lines and pools of 15-mer synthetic peptides span-
ning the entire sequence of L1 (Fig. 5). Peptide pool 121–153
was recognized by all six DRB1*0301-positive controls and was
the sole target of control 1, who was homozygous for
DRB1*0301. Responses within this pool were localized to pep-
tide 139–153 (sequence 5	 DNRVNVGMDYKQTQL 3	). This
peptide represents a region of L1 that is homologous between
HPV-6 and HPV-11 but not to the region in common cutane-
ous and genital HPV (HPV-1, HPV-2, HPV-3, HPV-4,
HPV-16 and HPV-18) (41) and that contains a binding motif
consistent with HLA-DRB1*0301 restriction (P1  V, P4  D,
P6  K [peptide residues 6, 9, and 11] [22] and bound strongly
to puriﬁed DRB1*0301 in a competition assay (data not
shown). Responses to other peptide pools were heteroge-
neous, reﬂecting differences in other HLA -class II alleles.
We attempted to establish short-term CD4
 T-cell lines from
four DRB1*0301-positive donors old enough to donate the vol-
ume of blood required for this experiment. A line could not be
established from patient 1 (three separate failures), who has se-
vere disease with lung parenchymal involvement. Lines were es-
tablished in three patients, and all three recognized peptide pool
121–153 (Fig. 6). Within the pool, all focused on p139. By chance,
these patients had the same second DR allele, and their responses
to the peptide pools were similar. Finally, the production of
IFN-, IL-4, and IL-10 by T-cell lines selected from two
DRB1*0301 patients and two DRB1*0301-positive controls in
response to the VLP and p139 was compared by using ELISpots.
The production of IFN- dominated responses to the VLP and
pool 121–153 in both patients and controls (Fig. 7).
Sequencing of HPV-11 L1. To determine if variation of pro-
liferative responses to L1 in DRB1*0301-positive patients was
a result of sequence variation within the immunodominant
DR3-restricted epitope, the L1 ORF of clinical isolates from
two HPV-11-positive donors who failed to respond to the
HPV-11 VLP (patients 1 and 7) and two donors who re-
sponded strongly to the VLP (patients 2 and 3) were se-
FIG. 3. Comparison of clinical status and proliferative responses to
HPV-11 L1 by patients with RRP. Proliferative responses of PBMC to
HPV-11 VLP from individuals with RRP were assessed by [
3H]thymi-
dine incorporation as detailed in the legend to Fig. 1. Results are
presented as SI. Clinical status was assessed by the method of Derkay
et al. (16). Results for DRB1*0301-positive patients are represented by
black circles, and results for DRB1*0301-negative patients are repre-
sented by black diamonds. A signiﬁcant negative correlation was ob-
served between the clinical status of juvenile-onset patients and the
magnitude of their proliferative responses to HPV-11 VLP (Spearman
rank correlation: r  0.89, P  0.012).
FIG. 2. Proliferative responses of RRP patients to HPV-11 L1 VLP and four control antigens. Proliferative responses of PBMC from
individuals with RRP to HPV-11 VLP (1, 5, or 10 g/ml), tetanus toxoid (Tet) (15 g/ml), inﬂuenza virus hemagglutinin (HA) [A/Beijing/32/92
(H3N2), 5 g/ml], PPD (200 U/ml), and KLH (10 g/ml) were assessed by [
3H]thymidine incorporation as detailed in the legend to Fig. 1. Results
are presented as SI.
VOL. 77, 2003 HLA CLASS II AND RRP 1933quenced. No sequence variation was identiﬁed in L1 (data not
shown).
Response of control donors to L1 and p139 when using
PBMC from patient A as APC. Finally, since sequence varia-
tion in L1 did not account for the failure of donors with severe
RRP to respond to the VLP, we were interested is discovering
if PBMC from a nonresponding DRB1*0301-positive patient
were capable of processing and presenting L1 to DRB1*0301-
positive control donors. Irradiated PBMC from patient 1, the
most severely affected individual, were used to present L1 and
p139 to 5-week-old L1-speciﬁc lines established form two
DRB1*0301-positive control donors (Fig. 8). Both donors re-
sponded to the HPV-11 VLP and to p139, indicating that
PBMC from the most severely affected patient in this study are
capable of processing and presenting L1.
DISCUSSION
The principal ﬁnding of this investigation is the identiﬁca-
tion of a genetic association between the presence of HLA
DRB1*0301 and susceptibility to RRP. This association is
novel and has not been identiﬁed in two previous studies. This
may be explained by the small number of patients in the ﬁrst
study (n  16, of whom only 6 were children) (9) and the fact
that the second study was conﬁned to HLA-DQB1 alleles in
adult patients (1). In the present investigation, the presence of
DRB1*0301 was associated with more severe disease, since the
three most severely affected patients were homozygous for
DRB1*0301. In addition, preliminary evidence is presented for
an HLA-DRB1*14 association in juvenile-onset disease and an
HLA-B*27 association in adult-onset disease. These additional
ﬁndings may reﬂect the clinical heterogeneity of RRP (15).
The HLA DRB1*0301 allele is part of the A1-B8-DR3 an-
cestral haplotype (HLA DQB1*0201, HLA DRB1*0301, C4B-
Sf, C4A-0, TNF-AGG, HLA-B*0801, HLA-Cw*0701, HLA-
A*01), which has been linked to several autoimmune diseases
(27). Analysis of linked class I and TNF alleles suggested that
the association was with HLA-DRB1*0301 itself, although it is
difﬁcult to exclude other closely linked variants on the basis of
genetic analysis alone (32).
The identiﬁcation of an association with an HLA class II
allele raised the possibility that susceptibility to RRP might be
the result of aberrant CD4
 T-cell responses. Several lines of
evidence indicate that cellular immunity plays an important
FIG. 4. Comparison of clinical status and proliferative responses to four control antigens by patients with juvenile-onset RRP. Proliferative
responses of PBMC from juvenille-onset RRP patients to tetanus toxoid, inﬂuenza virus hemagglutinin (A/Beijing/32/92 H3N2), PPD, and KLH
were assessed by [
3H]thymidine incorporation as detailed in the legend to Fig. 2. Results are presented as SI. Clinical status was assessed by the
method of Derkay et al. (16). Results for DRB1*0301-positive patients are represented by black circles, and results for DRB1*0301-negative
patients are represented by black diamonds. No signiﬁcant correlations were observed between clinical status and the magnitude of the
proliferative responses to any of the four control antigens by using Spearman rank correlation (inﬂuenza virus hemagglutinin, r  0.61, P  0.17;
PPD, r  0.43, P  0.35; KLH, r  0.46, P  0.30; tetanus toxoid, r  0.61, P  0.17).
1934 GELDER ET AL. J. VIROL.role in controlling HPV-mediated diseases. First, there is a
high incidence of HPV-associated diseases in individuals with
iatrogenic (e.g., allograft recipients) or acquired cell-mediated
(e.g., advanced human immunodeﬁciency virus infection) im-
mune deﬁciencies (2, 4, 24, 36); second, inﬁltrates of CD4

and CD8
 T cells and macrophages have been observed in
spontaneously regressing plane warts, (30, 35) common warts,
(7) genital warts, (13), and low-grade cervical intraepithelial
neoplasia (33). It is difﬁcult to examine T-cell responses to
intact HPV-11 directly since the virus does not grow in tissue
culture. Therefore, a pragmatic decision was made to examine
responses to highly puriﬁed HPV-11 VLP composed of the
FIG. 5. Responses of short-term CD4
 T-cell lines derived from DRB1*0301-positive control donors to HPV-11 L1 VLP. L1-speciﬁc T-cell
lines were established from six DRB1*0301-positive healthy controls by culturing PBMC with HPV-11 L1 VLP. Every 7 days, the emerging line
was recovered and restimulated with autologous irradiated PBMC which had been prepulsed with the VLP. On days 21, 28, and 35, the proliferative
responses of the emerging lines to HPV-11 L1 and the HPV-11 L1 peptide pools was examined. The lines were washed and cultured with
autologous irradiated PBMC prepulsed for 2 h with medium (control), HPV-11 L1 VLP (1, 5, and 10 g/ml), or L1 peptide pools (19 peptide pools
each containing ﬁve peptides). At 48 h, the cells were pulsed with [
3H]thymidine and harvested and analyzed as described in the legend to Fig.
1. Experiments were conducted in triplicate, and the geometric mean of results is shown. Black bars represent SI of 3; grey bars represent SI of
3. Error bars represent standard errors. The HLA class I types of the controls were as follows: control 1, HLA-A*0101/2*0201-17, B*0801/2 *15,
Cw*0701 *0303; control 2, HLA- A*0101/2 *0301/2, *0801 *4001, Bw6, Cw*0701 *1203; control 3, HLA-A*0101/2 *0201-17, B*0801 *4001, Bw6,
Cw*0701; control 4, HLA- A*01, B*0801/2 *3501-4, Cw*0701 *0401-3; and control 5, HLA- A*0101*0201-17, B*0801 *1801/2, Bw6, Cw*1203:
control 6, HLA- A*0101/2 *0201-17, B*0801/2 *3501/4, Cw*0701, *0401.
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 T-cell lines derived from DRB1*0301-positive patients to HPV-11 VLP. The responses of CD4
 T-cell
lines from three DRB1*0301-positive patients with RRP are shown. Experimental details are as in Fig. 2. The HLA class I types of the patients
were as follows: patient 3, HLA-A*01, *24, B*8, Cw*0701/6 *1601; patient 22, HLA- A*03 *3001, B*5701 *27, Cw*0202 *0602; and patient 23,
HLA- A*0101, B*0801/2 *4406, Cw*0501 *0701. Experiments were conducted in triplicate, and the geometric mean of the results is shown. Black
bars represent SI of 3; grey bars represent SI of 3. Error bars represent standard errors.
1936 GELDER ET AL. J. VIROL.surface coat protein L1, which are under investigation as po-
tential vaccines in genital HPV infection (25) and hence are
available as highly puriﬁed whole proteins, rather than to ex-
amine immune responses to early viral proteins (such as E6
and E7), which, while more directly involved in disease patho-
genesis, are not readily available as intact antigens.
All six HLA-DRB1*0301-positive controls exhibited signiﬁ-
cant proliferative responses to the HPV-11 VLP which were
comparable to those seen in non-DRB1*0301-positive con-
trols, indicating that DRB1*0301 itself is not a low-responder
allele. We then examined T-cell proliferative responses to
HPV-11 VLP in patients with RRP. These studies were ham-
pered by the geographical location of individual patients and
by difﬁculties in collecting adequate amounts of blood from
children; however, we were able to investigate 10 patients (7
with juvenile-onset disease). Considerable variation was ob-
served in the magnitude of their responses, and once again this
was not related to the presence or absence of the DRB1*0301
allele. Interestingly, however, the magnitude of the prolifera-
tive response to HPV-11 L1 VLP was inversely correlated with
the clinical status of the juvenile-onset patients, providing sup-
port for the genetic observation that susceptibility to RRP is
linked to polymorphisms in HLA class II alleles.
Detailed epitope mapping using CD4
 T-cell lines demon-
strated that the subset of DRB1*0301-positive patients capable
of responding to the HPV-11 VLP recognize the immunodom-
inant DRB1*0301-restricted L1 epitope, which is located
within a region with sequence identity between HPV-6 and
HPV-11 (but not to HPV-1 to HPV-4, HPV-16, and HPV-18
[41]). Responding patients also had a similar cytokine proﬁle
to normal HLA-DRB1*0301-positive controls. This indicates
that at least some patients with RRP have the capacity to
mount an apparently normal response to HPV-11 L1. By se-
quencing HPV isolated from papilloma tissue, we have ex-
cluded the possibility that nonresponders are infected with a
clade of HPV-11 with mutations in or around the immuno-
dominant DRB1*0301-restricted T-cell epitope.
The questions therefore arise why some patients have not
responded to HPV-11 L1 and why, although susceptibility to
RRP is linked to HLA DRB1*0301, T-cell proliferative re-
FIG. 7. Cytokine production by HPV-11 L1-speciﬁc T-cell lines assessed by ELISpot. The cytokine production proﬁles of two representative
short-term T-cell lines derived from two HLA DRB1*0301-positive controls and two HLA-DRB1*0301-positive patients were examined after 4
weeks of in vitro culture. L1-speciﬁc T-cell lines were activated for 48 h in triplicate at a density of 4  10
4 cells/150 ml of complete minimal Eagle
medium in 96-well U-bottom tissue culture plates with 10
4 autologous irradiated (3,000 rads) PBMC prepulsed for 2 h with either medium
(control), or L1 (5 g/ml), or relevant L1 peptide pools (5 g/ml), as previously determined by proliferative responses. As positive controls,
Lymphocult-LT (LC) or PMA plus ionomycin (PMA) was added 12 h before the cells were washed and transferred to precoated INF-, IL-4, or
IL-10 plates. After 16 h, the cells were discarded and cytokines were detected using ELISpot kits. After overnight drying at room temperature, the
colored spots were counted under a dissecting microscope. Geometric means of triplicate experiments are shown.
VOL. 77, 2003 HLA CLASS II AND RRP 1937sponses to HPV-11 VLP are not directly correlated to the
presence of this allele. We excluded the possibility that non-
responding patients have a major deﬁcit in HLA class II anti-
gen processing by demonstrating that PBMC from the most
severely affected patient in this study were capable of present-
ing both L1 and p139 to two DRB1*0301-positive control do-
nors. The possibility that nonresponding patients have a hole
in their T-cell receptor repertoire seems unlikely since we have
observed vigorous responses to L1 in patients who historically
have had extensive disease and are now either considerably
improved or in remission. A more attractive hypothesis is that
patients with severe disease have the capacity to respond to
HPV-11 L1 normally but that this response has been delayed
either because they have a low frequency of HPV L1-speciﬁcT
cells or because the response been modulated by immunoregu-
latory networks. Indirect support for a delay in the immune
response comes from the observations, noted above, that a
range of HPV-mediated diseases undergo spontaneous regres-
sion and that during this regression there is a prominent inﬁl-
tration of lymphocytes. There is also increasing evidence for
the important role of regulatory T cells in other conditions
including inﬂammatory bowel disease (6), which is also HLA
DRB1*0301 associated, albeit weakly (31), and it is conceiv-
able that the immune response in RRP has been delayed or
down regulated by regulatory networks which involve HLA
DRB1*0301 or a closely linked allele.
In conclusion, we have identiﬁed a genetic association be-
tween HLA DRB1*0301 and susceptibility to RRP. While the
mechanism underlying this association is unknown, it will be of
great interest to determine whether the presence of this allele
predicts clinical severity or response to therapy in prospective
studies.
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